Has the Worst Passed for Valeant Pharmaceuticals Intl Inc.?

After what can only be described as an epic collapse, Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:NRX) may have turned the first corner towards a long and slow recovery.

The Motley Fool

New CEO Joseph Papa may only be in his third week on the job at Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX), but he has already faced some tough questions and alleviated some fears, and more questions are surely to come over the next few weeks.

The new CEO met with investors this week and shed light on some of the challenges the company faces and the way to move forward. Valeant’s creditors had the option to force an early payment on loans and bonds after the company missed filing deadlines for financial records with regulators, which triggered default notices.

The company has been hit particularly hard over the past few months, when steep price increases on drugs caught the attention of U.S. lawmakers and regulatory bodies. Both Massachusetts and New York are conducting their own separate inquiries into patient-assistance and pricing programs.

Questionable practices with Philidor RX Services forced the collapse of that relationship last year, and a new deal with Walgreens Boots Alliance has been forged, albeit with some growing pains that Papa labeled as “speed bumps.”

A second phase of that program will launch later this summer, and Valeant is also working on new discount programs for some heart medications as well as other drugs that have been brought to the attention of U.S. Congress.

While it is a step in the right direction, Valeant still needs to do something about its debt.

Debt reduction

Valeant has a truly staggering amount of debt–nearly US$30 billion. Valeant announced this week that the company will target a debt reduction of at least US$1.5 billion this year. Funding for the reduction will be raised through the sale of specific non-core assets that exist outside of the company’s main franchises.

Assuming that a fair price is reached, Valeant has a number of attractive assets that could fetch billions. Core assets, as defined by the company include its dermatology products in the Bausch & Lomb brand, as well the gastroenterology products.

Some of those core assets, the Bausch & Lomb brand in particular, have a real value that is higher than the current stock price of Valeant. In that case, a partial spin-off of that asset might be what is needed for investors to see the value.

In a little under a year, Valeant has gone from being one of the best investments on the market to being one of the riskiest. While there is something to be said about the company being undervalued, the truth remains that Valeant is in a transitional state.

Currently, the stock trades at just over $36, down 74% year-to-date. While this may represent an opportunity to buy at a low price for those investors who believe the company will turn around, it’s too early to say with any certainty.

If the company can execute the plan set in motion to lower debt, keep core revenue-generating assets in house, and silence drug-pricing concerns through new alliances and discount programs, it will be well on the way to restoring some investor faith.

Fool contributor Demetris Afxentiou has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

oil pumps at sunset
Energy Stocks

How a $25,000 TFSA Could Fund Your Retirement

Canadians can turn to the TFSA to help provide a meaningful income stream in retirement.

Read more »

Canada day banner background design of flag
Investing

3 of the Best Canadian Stocks to Buy Right Now

These three Canadian stocks are ideal for balancing wealth-creation opportunities with stability and income generation in this uncertain outlook.

Read more »

Blocks conceptualizing Canada's Tax Free Savings Account
Dividend Stocks

TFSA Strategy: How to Earn $500 a Month in Tax-Free Dividend Income

Canadians can earn $500 in tax-free dividend income or another desired amount every month using a simple TFSA strategy.

Read more »

coins jump into piggy bank
Energy Stocks

Canadian Natural Resources vs. Enbridge: The Better Dividend Stock to Buy Today

Both CNQ and ENB have impressive payout records, consistently paying and increasing their dividends for decades.

Read more »

doctor uses telehealth
Dividend Stocks

TFSA Investors: This Monthly Dividend Stock Yields 7.6%

This REIT offers investors a monthly yield investors and a regular and frequent passive income stream to supplement their regular…

Read more »

shopper chooses vegetables at grocery store
Dividend Stocks

Loblaw vs. Empire: Which Grocery Stock Would I Choose for Long-Term Growth?

Both grocers benefit from repeat shoppers. I’d give Loblaw the edge for the ways it can earn more from those…

Read more »

Retirees sip their morning coffee outside.
Dividend Stocks

2 Canadian Stocks to Buy and Hold for 20 More Years

CP Rail (TSX:CP) and another outstanding Canadian stock that's more than worth holding for many decades.

Read more »

ETF is short for exchange traded fund, a popular investment choice for Canadians
Dividend Stocks

2 Top TSX ETFs to Buy and Hold in a TFSA Forever

Looking for top TSX ETFs for your TFSA? Explore how VFV and VDY combine U.S. stock exposure and Canadian dividends…

Read more »